In a report by Thomson Reuters LPC quoting anonymous sources, Valeant Pharmaceuticals had finalized tranche sizes on the new loan it had obtained for the US$8.7 billion of Bausch and Lomb. 

Under the new term loan A, Valeant had sold these to bank kenders and wa increased from US$500 million to US$850 million. The said loan would mature by April 2016.

The other term loan E, which is sold to institutional investors, has been reduced from US$3.55 billion to US$3.2 billion. The term loan E matures by 2020.

The pricing for the TLA was finalized at 225 basis point above LIBOR with 98.5 issue price. The TLE would be cleared 375 basis points above LIBOR with a 75 basis points LIBOR floor and with a 98.5 issue price.

The price differenc between the acquisition and the actual pricing at syndication is an indication of the market volatilty, making it increasingly difficult to obtain deals in the current US leveraged loan markeplace.